On November 11, 2012 Apexigen reported that its partner, Simcere Pharmaceutical Group has received approval from the State Food and Drug Administration of China to begin first-in-man trials with APX003, which is also known as BD0801, for the treatment of cancer (Press release Apexigen, NOV 11, 2012, View Source [SID:1234500906]). With this approval, APX003/BD0801 becomes the first humanized monoclonal antibody derived from Apexigen’s proprietary antibody technology platform to enter human trials.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

APX003/BD0801 is being developed in China through an active partnership between Apexigen and Simcere. Apexigen has collaborated with Simcere to add its antibody development expertise and experience to the advancement of the APX003/BD0801 program. This approval marks the success of the dedicated work of the collaboration team to file and defend an IND application, and initiates the next phase of collaboration in clinical development.

"We’re very pleased to see the IND approval for APX003/BD0801. This is an important milestone for our collaboration with Simcere and for proof-of-concept of our antibody technology platform" said Dr. Xiaodong Yang, President & CEO. "We look forward to continuing the collaboration with Simcere and advancing AXP003/BD0801 into clinical development."

APX003/BD0801 is a humanized monoclonal antibody directed against VEGF and is under development for the treatment of multiple malignancies.